Ranked among the top 10 global medical device companies as of revenue, General Electric is now about to file for an IPO to spin out its health-care unit GE Healthcare, as reported by CNBC. With the ongoing jump of Siemens Healthineers shares after their $5 Billion IPO, now GE Healthcare has caught the attention of investors in the medical device market. In this context, PatentSight shed light on the global top 10 medical device companies as of revenue in 2017 from a patent perspective.
In January of this year, U.S. pharmaceutical manufacturers Bristol-Myers Squibb (BMS) and Celgene Corporation announced they had entered into a definitive merger agreement for BMS to acquire Celgene.
The stated aim of the merger is to create ‘a premier innovative biopharma company’ with a particular focus on building an expanded offering in the cancer and immunotherapy space. If completed, the transaction is expected to cost $74 billion in a cash and stock deal, whereby Celgene shareholders will receive 1.0 BMS share as well as $50 in cash for each share of Celgene.
Our analysis of the two firms’ respective patent portfolios provides insight into how this merger would affect the U.S. pharma market. For this analysis, we employed our Patent Asset IndexTM methodology, which scientifically assesses patent families against Key Performance Indicators of Technology RelevanceTM and Market CoverageTM.
With the acquisition of Maxwell Technologies, Tesla expands its patent portfolio and includes technologies that may lead to a major advantage in the future technology of efficient batteries for electric cars. The company is a specialist in the field of energy storage. For Tesla this can mean a leap forward in the highly competitive field of battery technology for electric cars. A closer look at this acquisition scenario shows us in which technology areas Maxwell can significantly complement Tesla's patent portfolio.
You may have seen our recent press release but I wanted to personally express my excitement over the recent acquisition by LexisNexis® IP. We anticipate that as a result of this acquisition, we will be able to make significant enhancements to our product.
With added content, financial resources, and a broader customer base we will significantly accelerate our development. In particular, the advent of powerful self-learning algorithms often described as “artificial intelligence” is a great opportunity to reach the next breakthrough in patent analytics. We are thrilled to leverage our competence in high quality data and reliable science-based algorithms to continue leading the field with advanced tools that offer unique and reliable business insights.
Rest assured, many things you value about PatentSight will not change. PatentSight will continue under the leadership of myself and my team in the same offices in Bonn, Germany. All PatentSight employees will be retained and your current points of contact will not change. Our much-praised Consulting & Support Team will continue to serve you directly. The name of the product will change slightly to LexisNexis PatentSight.
We look forward to our continued relationship. Please contact me, Björn Ulmer or your main contact in the business development team if you have any additional questions.
In 2011 faced with “the impending loss of patent protection on certain leading products”, the Takeda Pharmaceutical Company unveiled its mid-term plan to achieve sustainable growth. Over the 10 years prior to this Takeda had pruned its patent portfolio significantly from over 3500 patent families in the year 2000 to less than 1900 in 2008, saving the company millions of dollars over the lifetime of these patents. Whilst such cost saving measures would have reduced the company’s liabilities, this alone would have not ensured long-term prosperity. Enter the “New Takeda”.
Tags: Mergers and Acquisitions
Becton Dickinson’s 24bn USD acquisition of U.S. peer C.R. Bard, as reported by Reuters, has secured its position as one of the top 10 global healthcare companies in terms of both revenue and innovation. Although the combined company will still wield a smaller patent portfolio than the industry giants, the average quality of the portfolio is significantly above average, surpassed only by Johnson & Johnson. This high quality means the combined entity now has 6th strongest portfolio in the field of healthcare, as defined by ip-search a division of the CHPTO, out of the top 30 medical device manufacturers, by annual revenue reported in MPO magazine.
An analysis of the patent portfolios of Broadcom Ltd. (AVGO), Qualcomm Inc.
(QCOM) and NXP Semiconductor (NXPI) by PatentSight GmbH, suggests that Qualcomm’s portfolio is rated highest among the three companies based on the Patent Asset Index (PAI).
The PAI is a scientifically developed and industry proven methodology to measure the
innovative strength of an enterprise or an entire technology field. It is calculated at the level of a patent portfolio as the sum of the competitive impact scores of the individual patent families contained in this portfolio. The competitive impact in turn is calculated based on the technology relevance (citation-based indicator) and market coverage (patent protection around the globe, calculated based on the potential economic value of each country) of a patent family. Depending on the question to be addressed the Patent Asset Index can be calculated for a company as a whole, or just for patents belonging to specific business areas or technology fields: it then shows the strength of the company in those particular domains only.